The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, personalization, and optimization.
has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor T-cell therapies and bispecific antibodies . These novel approaches have delivered unprecedented outcomes in heavily pretreated patients.
Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection.cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe:These agents deliver overall response rates of 60%-70% in heavily pretreated patients, with median progression-free survival of 12-18 months and overall survival of 24-30 months.in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, includingHowever, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance., which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. “Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,” said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs?, longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. “The treatment choices should always be based on research data, but understanding patients’ preferences is critical for shared decision-making,” she said. “With 19 new drugs or combinations approved in the past two decades, we’ve made incredible progress,” said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. “Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,” said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing improved tolerability. “These results showed deep and durable responses in a population with a significant unmet need,” Kumar said. Moreau, who was not involved in the study, added, “This could be the pivotal trial that leads to approval of the first bsAb combination.”JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. “Despite recent progress, we still need to reduce treatment burden and improve outcomes,” said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. “JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,” Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSKRodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. Cristina Ferrario is a molecular biologist and former researcher in molecular oncology at three institutes in Milan. She has a master's degree in communication and health from the University of Milan and a master's degree in cancer genetics from the University of Pavia. She has worked as a science journalist for more than 20 years.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Myeloma Plasma Cell Myeloma Biologic Therapy Biologics Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors CAR T Chimaeric Antigen Receptor T-Cell Therapy Chimaeric Antigen Receptors Chimaeric Immunoreceptors Chimaeric T-Cell Receptors Antigens Board Certification Boards
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
7 Expert-Approved Car Sex Positions That Go Way Beyond MissionaryWhen you think of car sex, images of awkward teenage fumblings probably come to mind. It’s a rite of passage for many, spanning generations and infusing pop culture, from AC/DC’s “Girls Got Rhythm” to LL Cool J’s “Backseat,” to Addison Rae singing, “losing all your innocence in the backseat” in “Diet Pepsi.
Read more »
Henry Ford Museum seeks vintage car mechanic | Car NewsThe Henry Ford Museum is looking for a vintage car mechanic to maintain and service its vehicle fleet.
Read more »
Subaru teases new high-performance sports car | Car NewsSubaru confirms it will unveil a new sports car at the upcoming Japan Mobility Show this fall.
Read more »
Rare earth shortage shutting down European car parts plants | Car NewsAuto parts factories in Europe are temporarily closing due to a shortage of rare earth elements; Chinese export restrictions are to blame.
Read more »
Judicial decisions creating tariff clarity for car industry | Car NewsRecent court rulings on the legality of the Trump administration's tariffs may be delivering more clarity to the North American automotive industry.
Read more »
Higher steel, aluminum tariffs could rattle car industry | Car NewsThe U.S. move to double tariffs on steel and aluminum could rattle automakers and their suppliers in North America.
Read more »